Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Update on treatment of light chain amyloidosis.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Mahmood S, et al. Among authors: sanchorawala v. Haematologica. 2014 Feb;99(2):209-21. doi: 10.3324/haematol.2013.087619. Haematologica. 2014. PMID: 24497558 Free PMC article. Review.
Adapting to AL amyloidosis.
Seldin DC, Sanchorawala V. Seldin DC, et al. Among authors: sanchorawala v. Haematologica. 2006 Dec;91(12):1591-5. Haematologica. 2006. PMID: 17145594 No abstract available.
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Reece DE, et al. Among authors: sanchorawala v. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. Blood. 2009. PMID: 19498019 Free article. Clinical Trial.
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Reece DE, et al. Among authors: sanchorawala v. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11. Blood. 2011. PMID: 21562045 Free article. Clinical Trial.
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; Velcade Can2007 Study Group. Dubrey SW, et al. Among authors: sanchorawala v. QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13. QJM. 2011. PMID: 21752867 Clinical Trial.
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Comenzo RL, et al. Among authors: sanchorawala v. Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. Leukemia. 2012. PMID: 22475872 Review.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Reece DE, et al. Among authors: sanchorawala v. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. Blood. 2014. PMID: 25202139 Free PMC article. Clinical Trial.
232 results